Corneal ulceration associated with dupilumab use in a patient with atopic dermatitis

PURPOSE: To describe a case of corneal ulceration associated with dupilumab use for atopic dermatitis. OBSERVATIONS: A patient developed an inflammatory corneal ulcer 3 weeks after starting bi-weekly intravenous dupilumab therapy. Symptoms resolved with topical prednisolone and discontinuation of th...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Gavin, Berkenstock, Meghan, Soiberman, Uri
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7415768/
https://www.ncbi.nlm.nih.gov/pubmed/32793843
http://dx.doi.org/10.1016/j.ajoc.2020.100848
_version_ 1783569196731334656
author Li, Gavin
Berkenstock, Meghan
Soiberman, Uri
author_facet Li, Gavin
Berkenstock, Meghan
Soiberman, Uri
author_sort Li, Gavin
collection PubMed
description PURPOSE: To describe a case of corneal ulceration associated with dupilumab use for atopic dermatitis. OBSERVATIONS: A patient developed an inflammatory corneal ulcer 3 weeks after starting bi-weekly intravenous dupilumab therapy. Symptoms resolved with topical prednisolone and discontinuation of the systemic therapy with dupilumab. CONCLUSION AND IMPORTANCE: Dupilumab is known to cause ocular surface inflammation, but we report a novel association between dupilumab use and potentially sight-threatening corneal ulceration.
format Online
Article
Text
id pubmed-7415768
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-74157682020-08-12 Corneal ulceration associated with dupilumab use in a patient with atopic dermatitis Li, Gavin Berkenstock, Meghan Soiberman, Uri Am J Ophthalmol Case Rep Case Report PURPOSE: To describe a case of corneal ulceration associated with dupilumab use for atopic dermatitis. OBSERVATIONS: A patient developed an inflammatory corneal ulcer 3 weeks after starting bi-weekly intravenous dupilumab therapy. Symptoms resolved with topical prednisolone and discontinuation of the systemic therapy with dupilumab. CONCLUSION AND IMPORTANCE: Dupilumab is known to cause ocular surface inflammation, but we report a novel association between dupilumab use and potentially sight-threatening corneal ulceration. Elsevier 2020-08-05 /pmc/articles/PMC7415768/ /pubmed/32793843 http://dx.doi.org/10.1016/j.ajoc.2020.100848 Text en © 2020 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Report
Li, Gavin
Berkenstock, Meghan
Soiberman, Uri
Corneal ulceration associated with dupilumab use in a patient with atopic dermatitis
title Corneal ulceration associated with dupilumab use in a patient with atopic dermatitis
title_full Corneal ulceration associated with dupilumab use in a patient with atopic dermatitis
title_fullStr Corneal ulceration associated with dupilumab use in a patient with atopic dermatitis
title_full_unstemmed Corneal ulceration associated with dupilumab use in a patient with atopic dermatitis
title_short Corneal ulceration associated with dupilumab use in a patient with atopic dermatitis
title_sort corneal ulceration associated with dupilumab use in a patient with atopic dermatitis
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7415768/
https://www.ncbi.nlm.nih.gov/pubmed/32793843
http://dx.doi.org/10.1016/j.ajoc.2020.100848
work_keys_str_mv AT ligavin cornealulcerationassociatedwithdupilumabuseinapatientwithatopicdermatitis
AT berkenstockmeghan cornealulcerationassociatedwithdupilumabuseinapatientwithatopicdermatitis
AT soibermanuri cornealulcerationassociatedwithdupilumabuseinapatientwithatopicdermatitis

Ejemplares similares